Form D · Other Health Care
Carbon Biosciences, Inc.
Boston, MA · CIK 0001906366
Offering snapshot reported Jan 25, 2022 · SEC filing
- Reported sold
- $38M Offering amount: $38M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 25, 2022 | Initial | $38,000,001 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-430736
Source: Form D, filed Jan 25, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Hadfield | Executive |
| Robert Kotin | Director, Executive |
| John Lawrence | Executive |
| Jacopo Leonardi | Director, Executive |
| Chen Schor | Director |
| David Steinberg | Director |
| Geeta Vemuri | Director |
| Derek Yoon | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
800 Boylston Street Suite 1555
Boston, MA, 02199
Boston, MA, 02199